CYDY · CytoDyn Inc.
$0.25
+0.00 (+0.04%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Oct 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company had an accumulated deficit of approximately $950.4 million as of August 31, 2026. These factors, among several others, raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Oct 14, 2026
Market Cap
$367.38M
Shares
1.47B
Volume · Oct 20
7.35M
Avg daily vol (3M)
1.68M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.25
Open$0.27
Day$0.24–0.29
52W close$0.19–0.37
Avg vol 30d1.8M
Short int36.3M · 2.5% float · 11.5d
Short vol75%
DataJan 2020–Oct 2026
Filing10-Q · Oct 14
Up next
filed Oct 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$57.09M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$19.45M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.4%
Year over year · more shares
Price change (1Y)
-3.8%
Trailing year
Short interest
2.5%
Latest settlement · 11.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+20%
above
RSI (14)
74
overbought
MACD trend
Positive
52-week position
35%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+22%
trailing
6-month return
−19%
trailing
YTD return
−11%
this year
Relative strength
−27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-33% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.47% of float · ▲ +0.3% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
Free cash flow
$-17.4M
Balance sheet
$26.5M
net debt
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
7.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+20%
Bullish
RSI (14)
74
Bearish
MACD trend
Positive
Bullish
52-week position
35%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-33% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.47% of float · ▲ +0.3% MoM · 11.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 35%
Range high $0
vs 200-day avg -1%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYDY
this stock
CytoDyn Inc.
|
$367.38M | -10.7% | -100.0% | — | 2.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
6
- % held
- 0.0%
- Net QoQ
- -170.5K sh
- Top holder
- Diversified Trust Co
Held
Float
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 19, 2026
- This year
- 12
CytoDyn appointed Robert E. Hoffman CEO effective October 20, 2026, while Jacob P. Lalezari resigned as CEO and became Head of Research and Translational Sciences. Hoffman will also remain principal accounting officer, with an annual base salary of $525,000.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYDY | +25.7% | +21.7% | -19.3% | +22.0% | -10.7% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +26.9% | +22.3% | -27.4% | +21.2% | -23.5% |